EPS for BioPharmX Corporation (BPMX) forecasted at $-0.02

May 17, 2018 - By Darrel Chase

BioPharmX Corporation (NYSEAMERICAN:BPMX) Corporate Logo

On June, 12 WallStreet expected BioPharmX Corporation (NYSEAMERICAN:BPMX)’s earnings release, as reported by RTT. Analysts predict $-0.02 earnings per share. That’s $0.05 up or 71.43 % from 2017’s earnings of $-0.07. BPMX is hitting $0.191 during the last trading session, after decreased 1.55%.Currently BioPharmX Corporation is downtrending after 50.58% change in last May 17, 2017. BPMX has also 2.24 million shares volume. BPMX underperformed the S&P500 by 62.13%.

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets.The firm is valued at $36.58 million. The firm offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC).Currently it has negative earnings. The Company’s clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.